Difference between revisions of "Part:BBa K2549021"

Revision as of 18:09, 17 October 2018

aCD19-mN1c-tTAA

This part is one of our SynNotch receptors, similar to the original published version^[1]. It is our favorite. αCD19 (Part:BBa_K2549005) is used as the extracellular sensor module to receive the signal input from surface-expressed CD19. mN1c (Part:BBa_K2549006) is served as the transmembrane core domain of SynNotch, which is evident to have a low basal expression and a high activation efficiency. tTAA (Part:BBa_K2446057) is an improved tetracycline-controlled transactivator^[2], which is cleaved after SynNotch activation and drives the expression of the amplifier. Besides, a CD8α signal peptide (Part:BBa_K2549044) and a Myc-tag (Part:BBa_K823036) are added to the N terminal of αCD19 (Part:BBa_K2549005) for membrane targeting and easy determination of surface expression.

Sequence and Features

Biology

Our characterization

Flow cytometry results of SynNotch activation. surAg, surface antigens, which was surface-expressed CD19 for αCD19-SynNotch or surface-expressed EGFP for LaG-SynNotch, respectively. Without surAg, the EGFP (Y axis, driven by tTAA released after SynNotch activation) was low, and it went high after adding surAg. More details please visit http://2018.igem.org/Team:Fudan/Results and http://2018.igem.org/Team:Fudan/Optimization .

It is obvious that αCD19-mN1c-tTAA can be significantly activated by surface-expressed CD19. It also has the highest signal-to-noise ratio among all the SynNotch receptors that we submitted. Besides, it has a lower background activation ratio comparing to others.

Flow cytometry results of an ENABLE OR gate. ENABLE OR gate using tTAA and GV2 as the Amplifiers. RFI: output from the Combiner after surAg activation was divided by the value before activation. Similar to tTAA, GV2 works well as an Amplifier. The TRE3GV, URE2G promoters in the Combiner receive signals from tTAA and GV2, respectively. More details please visit http://2018.igem.org/Team:Fudan/Results and http://2018.igem.org/Team:Fudan/Measurement .

It is obvious that LaG16-2-mN1c-GV2 (Part:BBa_K2549020) and αCD19-mN1c-tTAA (Part:BBa_K2549021) perform well as the Receptors for ENABLE OR gate.

Clinical significance of anti-CD19

Please refer to our basic Part:BBa_K2549005 for more details.

SynNotch receptors function well in Morsut L et al 2016

Morsut L et al stated:SynNotch receptors provide extraordinary flexibility in engineering cells with customized sensing/response behaviors to user-specified extracellular cues.

Morsut L et al have shown that modularity of the synNotch platform. They stated: the input and output domains from Notch can be swapped with diverse domains. On the extracellular side, diverse recognition domains can be used (antibody based, or peptide tags are shown) and on the intracellular side, diverse effector can be used (transcriptional activators with different DNA-binding domains are shown, as well as a transcriptional repressor).

Please refer to the original article for more details.

References

1. ↑ Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. Morsut L, Roybal KT, Xiong X, ..., Thomson M, Lim WA. Cell, 2016 Feb;164(4):780-91 PMID: 26830878; DOI: 10.1016/j.cell.2016.01.012
2. ↑ Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Urlinger S, Baron U, Thellmann M, ..., Bujard H, Hillen W. Proc Natl Acad Sci U S A, 2000 Jul;97(14):7963-8 PMID: 10859354